Abstract
This brand new report examines the prospects for the growth of pharmaceutical
revenues in China. Visiongain predicts that total pharmaceutical revenues in
China will increase from approximately $12bn in 2007 to over $30bn in 2013.
This is a considerable increase, one that will represent a near tripling of
total sales over six years. Strong growth will continue well beyond that
period, as this report shows and explains.
Over 220 pages full of analysis, graphs, tables and charts - available to you today.
If you are interested in pharmaceutical business in China, you cannot afford
to be without this report by visiongain' s leading authority on developing
pharmaceutical markets.
- The growth of pharmaceutical markets in the developing nations has the
potential to offset the slowdown of sales growth in developed markets of North
America, Europe and Japan.
- Visiongain predicts that China will exhibit very strong pharma sales
growth from 2008-2023. Rapid economic growth and a vast, currently
under-served population, will drive that expansion. There will be significant
growth in sales of both branded and generic drugs through increasing demand
from both public and private healthcare sectors.
Visiongain' s Chinese Pharmaceutical Outlook 2008-2023 examines the exciting
Chinese pharmaceutical market and industrial sector critically through
comprehensive research and analysis. Visiongain applied techniques such as
financial forecasting, surveying of key opinion leaders, SWOT analyses and
discussion of qualitative factors. Societal, political, economic and
commercial issues are covered. The result is a comprehensive market-based
report with detailed analysis and informed opinion. This original 220+ page
study contains 57 tables and 47 figures. We invite you to examine the table of
contents included here.
In particular, visiongain' s Chinese Pharmaceutical Outlook 2008-2023 concentrates on the following themes:
- A forecast of the global pharmaceutical market from 2007-2023, with key
issues discussed
- Forecasts of sales revenues and growth rates for Chinese pharmaceutical
sales from 2007-2023, including key market segments such as Rx, OTC, domestic
and foreign sales - all with comprehensive discussion
- Forecasts of sales for leading therapeutic areas and pharma products
- Revenue forecasts for clinical outsourcing in China and relevant discussion
- Revenue forecasts for contract manufacturing in China and relevant
discussion
- Drivers and opportunities in the Chinese pharmaceutical sector
- Restraints and threats in that market and industry
- Discussion of key domestic players and important therapeutic areas,
including biotechnology, drug development and joint ventures
- Discussion of regulatory, societal and economic issues
Why you should buy this report:
- To receive a comprehensive analysis of the Chinese pharma market and
industry from 2007-2023, with both quantitative and qualitative aspects covered
- To discover predicted revenues, sales growth rates and other key metrics
for the Chinese pharma sector from 2006-2023
- To determine the forces that influence pharmaceutical sales and related
developments in China:
- Competitive characteristics of the market and industry
- Regulatory, technological, societal and political issues
- Drivers and restraints
- Strengths, weaknesses, opportunities and threats
- Expert opinion from China, as obtained by visiongain
- To find out where the Chinese market is heading - both commercially and
technologically - including regulatory issues
- To determine key activities of leading companies
- To receive a comprehensive discussion of healthcare provision in China,
both public and private.
The dominant pharmaceutical markets of North America, Western Europe and Japan
currently account for over 80% of revenues for prescription drugs worldwide.
However, there is great concern about the relatively low growth of those
established markets in recent years. Consequently, international
pharmaceutical companies are striving to raise their profiles in the
developing markets of Asia, Latin America and Eastern/Central Europe.
Principal amongst those developing markets is the emergent demographic and
economic colossus of China.
Growth of the pharmaceutical markets in developing nations will clearly
surpass that of the established markets throughout the foreseeable future.
That situation will provide one of the greatest opportunities ever available
to the international pharmaceutical industry. Those strongly growing national
economies drive the reform and broadening of healthcare systems, with
increasing sales in all healthcare sectors. Improvements in both the quality
and reach of these healthcare provisions will drive the sales of branded and
generic drugs in particular. This report will help you to understand those
developments and opportunities.
Other benefits to you when you order this report:
- Full searchable report when you buy the company or corporate editions
- Copies can be easily printed for offline reading
View Cart
